AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6109991 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (SS)
Number of subjects: 0
Study 31997084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus 300 mg green tea extract
Number of subjects: 12
Study 31997084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus 600 mg green tea extract
Number of subjects: 12
Study 31997084 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg alone
Number of subjects: 12
Study 30471953 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T co-administered with MenACWY-TT vaccine (Group A; n=104)
Number of subjects: 312
Study 30471953 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV-HB-PRP-T vaccine alone (Group B; n=105)
Number of subjects: 312
Study 30471953 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-TT vaccine alone (Group C; n=103)
Number of subjects: 312
Study 27884241 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy alone
Number of subjects: 607
Study 24816141 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal low current stimulation of gamma activity during REM sleep
Number of subjects: 0
Study 24816141 — intervention group
Group type: COMPARATOR
Intervention: Other stimulation frequencies (not specified)
Number of subjects: 0
Study 23050750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 37
Study 23050750 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 37
Study 20670451 — intervention group
Group type: EXPERIMENTAL
Intervention: Banha-sasim-tang
Number of subjects: 100
Study 20670451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18713194 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty index (FI) as a measure to describe the types of people included in the study
Number of subjects: 315
Study 16512468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini laparoscopic cholecystectomy (MLC)
Number of subjects: 80
Study 16512468 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 80
Study 15257733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation + application of 8.5% w/w doxycycline gel (Atridox)
Number of subjects: 103
Study 15257733 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical scaling/root planing (Control)
Number of subjects: 103
Study 11853599 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 41
Study 11853599 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 41
Study 9193198 — intervention group
Group type: EXPERIMENTAL
Intervention: L-745,870 (15 mg/d)
Number of subjects: 38
Study 9193198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9193198 — intervention group
Group type: EXPERIMENTAL
Intervention: L-745,870
Number of subjects: 38
Study 1539847 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.1 mg.kg‐1, iv)
Number of subjects: 95
Study 1539847 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac (0.9 mg.kg‐1, iv)
Number of subjects: 95
Study 1539847 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 95
Study 4078154 — intervention group
Group type: COMPARATOR
Intervention: Attention-related late positive wave (P400) in AN group
Number of subjects: 37
Study 4078154 — intervention group
Group type: COMPARATOR
Intervention: Attention-related late positive wave (P400) in PA group
Number of subjects: 37
Study 29858913 — intervention group
Group type: EXPERIMENTAL
Intervention: mPNL
Number of subjects: 97
Study 29858913 — intervention group
Group type: COMPARATOR
Intervention: standard PNL
Number of subjects: 97
Study 29886062 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback (VF)
Number of subjects: 38
Study 29886062 — intervention group
Group type: COMPARATOR
Intervention: Control training without video feedback
Number of subjects: 38
Study 26742474 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge mortality risk after hospitalization for heart failure
Number of subjects: 3993
Study 26742474 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted mortality rate immediately after discharge
Number of subjects: 3993
Study 26742474 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk variation between quintiles of risk
Number of subjects: 3993
Study 26742474 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted mortality risk during the 90 days preceding subsequent heart failure readmission
Number of subjects: 3993
Study 26742474 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term interventions for high mortality risk patients
Number of subjects: 3993
Study 24905206 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning instruction based on the self‐regulated strategy development model
Number of subjects: 192
Study 24905206 — intervention group
Group type: COMPARATOR
Intervention: Standard writing instruction
Number of subjects: 192
Study 22313803 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI
Number of subjects: 152
Study 19684423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT)
Number of subjects: 32
Study 19684423 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 32
Study 18278698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specifics not provided)
Number of subjects: 0
Study 18278698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics and pharmacogenomics (individualisation of therapy)
Number of subjects: 0
Study 18278698 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from registries and observational trials
Number of subjects: 0
Study 15973098 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 134
Study 15973098 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan technique (MM)
Number of subjects: 134
Study 15973098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 134
Study 12618256 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg sublingual misoprostol 3 h prior to vacuum aspiration (VA)
Number of subjects: 100
Study 12618256 — intervention group
Group type: COMPARATOR
Intervention: No premedication for cervical ripening (Control)
Number of subjects: 100
Study 9805361 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-provided elaborations
Number of subjects: 0
Study 9805361 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated elaborations
Number of subjects: 0
Study 9805361 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally relevant elaborations
Number of subjects: 0
Study 8608073 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml 0.5% plain bupivacaine
Number of subjects: 53
Study 8608073 — intervention group
Group type: COMPARATOR
Intervention: 2 ml 0.75% hyperbaric bupivacaine premixed in 8.25% glucose
Number of subjects: 53
Study 2669036 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose total body irradiation (STBI) - 10 Gy at a 4.5 cGy/min dose rate, 8 Gy to the lungs
Number of subjects: 54
Study 2669036 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated total body irradiation (HTBI) - 13.2 Gy in 11 fractions, 3 fractions per day, 9 Gy to the lungs
Number of subjects: 54
Study 23362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% selenium disulfid suspension
Number of subjects: 2610
Study 23362 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2610
Study 29484551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetico-deduction
Number of subjects: 88
Study 29484551 — intervention group
Group type: COMPARATOR
Intervention: Self-explanation
Number of subjects: 88
Study 27932871 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided therapy
Number of subjects: 220
Study 27932871 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided therapy
Number of subjects: 220
Study 24978348 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 580
Study 24978348 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety (after controlling for covariates)
Number of subjects: 580
Study 24978348 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety (among men)
Number of subjects: 580
Study 24978348 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety (among women)
Number of subjects: 580
Study 23122802 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter Aortic Valve Replacement (TAVR) via transfemoral access (TF)
Number of subjects: 0
Study 23122802 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter Aortic Valve Replacement (TAVR) via transapical access (TA)
Number of subjects: 0
Study 23122802 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (AVR)
Number of subjects: 0
Study 20975109 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein and leucine supplementation (19.7 g of whey protein and 6.2 g of leucine)
Number of subjects: 30
Study 20975109 — intervention group
Group type: COMPARATOR
Intervention: Calorie-equivalent placebo
Number of subjects: 30
Study 18552703 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day maximum dose)
Number of subjects: 11
Study 18552703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16014407 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 300 microg/d
Number of subjects: 562
Study 16014407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 12486924 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical techniques
Number of subjects: 0
Study 12486924 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 0
Study 9973009 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal pacing
Number of subjects: 14
Study 9973009 — intervention group
Group type: COMPARATOR
Intervention: Apical pacing
Number of subjects: 14
Study 7481023 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Initial dose of 8 ml bupivacaine 0.25% (20 mg) with epinephrine 1/200,000 and 50 micrograms fentanyl followed by continuous infusion of 8 ml/h bupivacaine 0.125% (10 mg/h) with epinephrine 1/400,000
Number of subjects: 101
Study 7481023 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Initial dose of 10 ml bupivacaine 0.125% (12.5 mg) with epinephrine 1/400,000 and 50 micrograms fentanyl followed by continuous infusion of 12 ml/h bupivacaine 0.0625% (7.5 mg/h) with epinephrine 1/800,000 and 12 micrograms/h fentanyl
Number of subjects: 101
Study 7481023 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Initial dose same as group A, but maintenance through a patient‐controlled (PCA) system with 5 ml bupivacaine 0.25% (12.5 mg) and epinephrine 1/200,000 set for a minimum interval of 1 h
Number of subjects: 101
Study 2196631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) at a plasma level of 80 +/- 20 ng/ml, monitored weekly over 8 weeks.
Number of subjects: 52
Study 2196631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (2-mg single doses)
Number of subjects: 0
Study 22419 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5-mg single doses)
Number of subjects: 0
Study 22419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6388971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5)
Number of subjects: 0
Study 6388971 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated T+ and T4+ cells)
Number of subjects: 0
Study 6388971 — intervention group
Group type: COMPARATOR
Intervention: Control (T- B-enriched cells)
Number of subjects: 0
Study 30999915 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (ASMQ) fixed dose combination, 25/55 mg AS/MQ administered once a day for 3 days
Number of subjects: 472
Study 29880750 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g) with low-nutrient drink (beef soup; 18 kcal)
Number of subjects: 8
Study 29880750 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g) with high-nutrient drink (75 g dextrose; 255 kcal)
Number of subjects: 8
Study 27521811 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence Reinforcement Therapy (ART) which includes cognitive-behavioral telephone counseling (TC), telemedicine clinic for nicotine replacement (NRT), and mobile contingency management (mCM)
Number of subjects: 310
Study 27521811 — intervention group
Group type: COMPARATOR
Intervention: Best practice control consisting of telephone counseling (TC) and telemedicine (NRT)
Number of subjects: 310
Study 25490675 — intervention group
Group type: EXPERIMENTAL
Intervention: H1/IC31 vaccine
Number of subjects: 48
Study 25490675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22414157 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone/demeclocycline (Ledermix)
Number of subjects: 109
Study 22414157 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Provicol)
Number of subjects: 109
Study 21162437 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 60% VO2 peak
Number of subjects: 48
Study 21162437 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest (Control)
Number of subjects: 48
Study 17686832 — intervention group
Group type: EXPERIMENTAL
Intervention: Salba (37 ± 4 g/day)
Number of subjects: 20
Study 17686832 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 20
Study 15596419 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU, 80 mg bid)
Number of subjects: 76
Study 15596419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 11983659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) ketorolac (maximum of 15 mg) six hourly postoperatively for 36 hr
Number of subjects: 35
Study 11983659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11983659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) ketorolac
Number of subjects: 35
Study 9818634 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 or 30 mg/day
Number of subjects: 475
Study 9818634 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 or 60 mg/day
Number of subjects: 475
Study 9818634 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 10 or 15 mg/day
Number of subjects: 475
Study 9818634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 60 or 90 mg/day
Number of subjects: 475
Study 9818634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 7814986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted (LAC)
Number of subjects: 42
Study 7814986 — intervention group
Group type: COMPARATOR
Intervention: Standard laparotomy (SC)
Number of subjects: 42
Study 2804191 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 23
Study 2804191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 4785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (50 micrograms in each nostril four times a day)
Number of subjects: 35
Study 4785 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol preparation identical in appearance
Number of subjects: 35
Study 31550199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing support program in addition to routine nursing care
Number of subjects: 0
Study 31358032 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-based algorithm to guide antibiotic use
Number of subjects: 200
Study 31358032 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 28099485 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 20
Study 28099485 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted H5N1 vaccine
Number of subjects: 20
Study 25877784 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program (2 supervised gym sessions and 1 home-based session per week)
Number of subjects: 147
Study 25877784 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 24026560 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/day
Number of subjects: 217
Study 24026560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 21333092 — intervention group
Group type: EXPERIMENTAL
Intervention: ECL diode laser‐assisted endonasal DCR without partial anterior middle turbinectomy
Number of subjects: 91
Study 21333092 — intervention group
Group type: COMPARATOR
Intervention: Partial anterior middle turbinectomy and ECL diode laser‐assisted endonasal DCR
Number of subjects: 91
Study 19651918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11
Study 19651918 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 11
Study 19651918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17596795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-DPT vaccine (3 doses)
Number of subjects: 2679
Study 17596795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-DPT vaccine (2 doses)
Number of subjects: 2679
Study 17596795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-DPT vaccine
Number of subjects: 2679
Study 15488051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 15488051 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and Propofol
Number of subjects: 40
Study 10924610 — intervention group
Group type: COMPARATOR
Intervention: Autologous buffy coat-reduced RBC transfusions (Group 1)
Number of subjects: 44
Study 10924610 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic buffy coat-reduced RBC transfusions (Group 2)
Number of subjects: 44
Study 10924610 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBC transfusions (Group 3)
Number of subjects: 44
Study 10924610 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvaged blood only (Group 4)
Number of subjects: 44
Study 8799530 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg microenema
Number of subjects: 6
Study 8799530 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg orally
Number of subjects: 6
Study 8799530 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg as a 60 min i.v. continuous infusion
Number of subjects: 6
Study 8799530 — intervention group
Group type: COMPARATOR
Intervention: Suppositories
Number of subjects: 6
Study 1600971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepdown regimen of propofol (10 mg kg‐1 h‐1 for 10 min, 8 mg kg‐1 h‐1 for the next 10 min, 6 mg kg‐1 h‐1 thereafter)
Number of subjects: 44
Study 1600971 — intervention group
Group type: COMPARATOR
Intervention: Steady rate infusion of propofol (6 mg kg‐1 h‐1)
Number of subjects: 44
Study 1600971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Stepdown and Steady rate infusion)
Number of subjects: 44
Study 2858186 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 45
Study 2858186 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 45
Study 31466813 — intervention group
Group type: EXPERIMENTAL
Intervention: NCHT (Neoadjuvant Chemohormonal Therapy)
Number of subjects: 177
Study 31466813 — intervention group
Group type: EXPERIMENTAL
Intervention: NHT (Neoadjuvant Hormonal Therapy)
Number of subjects: 177
Study 31466813 — intervention group
Group type: COMPARATOR
Intervention: No-NT (No Neoadjuvant Therapy)
Number of subjects: 177
Study 29792940 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 162
Study 29792940 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Number of subjects: 162
Study 29792940 — intervention group
Group type: COMPARATOR
Intervention: Sham laser therapy
Number of subjects: 162
Study 25171552 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1500 mg/day) + piperine (15 mg/day)
Number of subjects: 89
Study 25171552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25913052 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization (CIC)
Number of subjects: 90
Study 25913052 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone ointment CIC
Number of subjects: 90
Study 25913052 — intervention group
Group type: EXPERIMENTAL
Intervention: Contractubex ointment CIC
Number of subjects: 90
Study 25913052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 90
Study 23017624 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental walking and home-based strength training
Number of subjects: 66
Study 23017624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 20883592 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training‐Oregon Model (PMTO™)
Number of subjects: 0
Study 18697847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 885
Study 18697847 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational intervention
Number of subjects: 885
Study 16868325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch (0.2 mg/h)
Number of subjects: 22
Study 16868325 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (adhesive patch without active ingredient)
Number of subjects: 22
Study 12539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (150 IU, 3 times a day for 24 weeks)
Number of subjects: 12
Study 12539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (150 IU, 3 times a day for 48 weeks)
Number of subjects: 12
Study 12539025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10962867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg od for seven days
Number of subjects: 40
Study 10962867 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g/day i.v. for a total of 10 days
Number of subjects: 40